New drug duo aims to outsmart resistant ovarian cancer
NCT ID NCT05715216
First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding an experimental drug called etigilimab to the immunotherapy nivolumab can help control clear cell ovarian, fallopian tube, or primary peritoneal cancers that no longer respond to platinum chemotherapy. The study enrolls about 23 adults with platinum-resistant disease. Researchers will measure how many participants' tumors shrink or stabilize for at least four months, and track any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- etigilimab and nivolumab
- What this could lead to
- If successful, this combination could offer a new treatment option for people with platinum-resistant clear cell ovarian cancer, potentially shrinking tumors or delaying progression.
- What could go wrong
- This is a small, early-phase trial (23 participants) with no control group. The combination may not work better than existing options and could cause side effects like immune-related inflammation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL FALLOPIAN TUBE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?
- Can a custom mRNA vaccine keep ovarian cancer from coming back?
- Can a cancer pill keep working outside the lab? a Real-World test begins
- Can a Patient's own immune cells be supercharged to fight ovarian cancer?
- Can a new drug ST316 shrink Hard-to-Treat tumors?